On December 20, 2024, the UK Medicines and Healthcare products Regulatory Agency (MHRA) emphasized the importance of Post-Market Surveillance (PMS) by announcing the final PMS Statutory Instrument (PMS SI) as the Medical Devices (Post-Market Surveillance Requirements) (Amendment) Regulations 2024 (SI 2024 No. 1368). While most of the PMS SI requirements align with EU PMS requirements, new requir..
